|
Rituximab bei ANCA-Vaskulitis: Premiere einer Transparenz-Studie
Deutsches Ärzteblatt Boston – Eine randomisierte Studie in einer eher seltenen klinischen Indikation könnte nicht nur den Betroffenen mit ANCA-assoziierter Vaskulitis nutzen, für die eine Behandlung mit dem Antikörper Rituximab die bessere Wahl sein könnte. Die Studie im … |
Rituximab therapy effective for ANCA-associated vasculitisPhys.OrgIn an article published today in the New England Journal of Medicine, Immune Tolerance Network (ITN) researchers demonstrated that a single course of rituximab therapy (anti-CD20; Rituxa…
Rituximab noninferior to conventional therapy in ANCA-associated vasculitis …2 Minute Medicine1. At 18 months, patients with ANCA-associated vasculitis treated with one course of rituximab had similar outcomes in terms of inducing remission when comp…
|
Rituximab Equally Effective for Remission of Vasculitis
Monthly Prescribing Reference (HealthDay News) – Rituximab is as effective as conventional immunosuppressive therapy in maintaining remission in patients with severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, according to a study published in the Aug. 1 issue … Rituximab noninferior to conventional therapy in ANCA-associated vasculitis …2 Minute Medicine |
Therapy for severe vasculitis shows long-term effectivenessNational Institutes of Health (press release)Administering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with…
|
TrialShare portal strikes blow for data transparency
PharmaTimes … is debuting its TrialShare portal in conjunction with the publication in the New England Journal of Medicine of 18-month results from the Network’s RAVE trial of the B-cell depleting agent rituximab in Wegener’s Granulomatosis and Microscopic … |
NIH-funded study finds that rituximab is as effective as standard therapy for …News-Medical.netAdministering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with severe…
The IN VIVO Blog (blog) |
Deals Of the Week, Once Again, Ponders Biosimilars
The IN VIVO Blog (blog) Like their competitors, Teva and Lonza held much of their work close to their vests, but they had counted on developing a franchise around a biosimilar version of Roche’s $7 billion Rituxan (rituximab) franchise, only to halt clinical development last … |
|
Oral steroid-free maintenance therapy effective in most patients with lupus …
Healio Using a steroid-avoiding “rituxilup” protocol, researchers in London reported the outcomes of 50 patients (median age, 45 years; 39 women) with active lupus nephritis who received two doses of rituximab (1 g) and methylprednisolone (500 mg) on days 1 … |
GA101 Shows Gains in Pivotal CLL TrialOncLiveThe agent also delivered higher response rates than rituximab (Rituxan) plus chlorambucil did in the same population, although full data comparing the two antibodies in a head-to-head stage of the phase III …